"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

NCT06067061 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped insufficient recruitment

Conditions

Triple Negative Breast Neoplasms

Interventions

COMBINATION_PRODUCT: Atezolizumab + RP1

Sponsor

Institut Curie

Collaborators

[object Object]
[object Object]